Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Laboratoire Biodim prepares new anti-HIV agents

Nov. 13, 2012

Laboratoire Biodim discloses new agents for HIV infection

Nov. 9, 2012

Immune Response BioPharma publishes full results from phase III study of HIV vaccine

Nov. 5, 2012

Phase II study of GS-7340 meets 24-week primary objective

Nov. 5, 2012

British and French group presents novel vaccines for AIDS

Nov. 5, 2012

Shionogi and ViiV Healthcare form new integrase inhibitor agreement

Oct. 30, 2012

CytoDyn acquires antibody inhibiting HIV entry

Oct. 18, 2012

City of Hope discloses new siRNA systems for HIV

Oct. 11, 2012

Shionogi-ViiV Healthcare completes initial registration package for dolutegravir

Oct. 5, 2012

U.S. government awards GeoVax a grant for its HIV vaccine program

Oct. 3, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...